This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Response to the MHRA’s consultation on EU Exit no-deal contingency legislation

Published: 01 Nov 2018 in

The overall approach in no-deal Brexit is for the MHRA to be a stand-alone medicines and medical devices regulator, taking any decisions and carrying out any functions which are currently taken or carried out at EU-level. In this consultation response, the Society and Faculty of Pharmaceutical Medicine provide feedback regarding MHRA’s no-deal proposals on medicines, clinical trials and medical devices, and call for greater clarification regarding MHRA legislation and regulatory processes in the event of EU exit no-deal.

Read our response